Addressing therapeutic needs in oncology and infectious diseases through data driven innovation

Learn more about Globavir’s recent news items

Immuno - Oncology

Globavir's Immuno-Oncology pipeline includes preclinical 505(b)(2) candidates for IDO, TDO, A2AR, and other IO pathways, with our first candidates expected to enter clinical trails in 2017.

Discovery Platform

Globavir's Drug Discovery Platform (GDDP) utilizes cheminformatics algorithms and cutting-edge machine learning technology designed to accelerate drug candidates to the clinic.

Infectious Diseases

Globavir's Infectious Disease pipeline includes GBV006, our broad spectrum Phase II antiviral asset undergoing evaluation for the treatment of Ebola, Dengue, and RSV viral infections.